Treatment of refractory autoimmune diseases with ablative immunotherapy
- 29 February 2004
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 3 (2) , 21-29
- https://doi.org/10.1016/s1568-9972(03)00083-1
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Transcriptional Mechanisms Underlying Lymphocyte ToleranceCell, 2002
- CD4+CD25+ suppressor T cells: more questions than answersNature Reviews Immunology, 2002
- CD40 Ligand Functions Non-Cell Autonomously to Promote Deletion of Self-Reactive ThymocytesThe Journal of Immunology, 2002
- The T-cell repertoire available for recognition of self-antigensCurrent Opinion in Immunology, 2001
- Treatment of refractory autoimmune haemolytic anaemia with anti‐cd20 (rituximab)British Journal of Haematology, 2001
- Changes in autoimmune thyroid disease following allogeneic bone marrow transplantationBone Marrow Transplantation, 2001
- Intense Immune Suppression for Systemic Lupus—The Role of Hematopoietic Stem CellsJournal of Clinical Immunology, 2000
- Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphomaBiochemical Society Transactions, 1997
- The CAMPATH‐1 antigen (CDw52)Tissue Antigens, 1990
- Thymic Requirement for Clonal Deletion During T Cell DevelopmentScience, 1989